MediSpend and Life Sciences Subsidiary of RLDatix Merge to Form Leading Global Provider of Regulatory and Compliance SaaS Solutions for Life Sciences

PORTSMOUTH, N.H. – MediSpend and RLDatix Life Sciences, a subsidiary of RLDatix, today announced a definitive agreement to merge, creating a new unified company at the forefront of life sciences innovation and compliance. The new company offers the most comprehensive suite of software, data and workflow tools to support the entire lifecycle for global compliance, transparency, and sales enablement for the life sciences industry. The combined company currently serves over 300 pharmaceutical, biotech, and medical device companies worldwide.

Backed by Five Arrows (the alternative assets arm of Rothschild & Co.), Susquehanna Growth Equity, TA Associates, and Nordic Capital, the new company brings together RLD Life Sciences' expertise in providing services for pharmaceutical product development, commercialization, and distribution with robust compliance, and sales enablement alongside MediSpend's best-in-class transparency, stakeholder engagement, and data solutions supporting both commercial and clinical stakeholders.

MediSpend brings innovative technology that enables life sciences companies to grow their businesses compliantly through SaaS-based Stakeholder Engagement, Event Management, Spend Transparency, and advanced Clinical Data Document Anonymization and Redaction capabilities.

RLDatix Life Sciences contributes unmatched subject matter expertise and market-leading skills by empowering life sciences companies to master complexity, mitigate risk, and continually exceed the standards of compliance - from Government Pricing to Learning and Development.

This strategic integration empowers pharmaceutical and life sciences companies to accelerate innovation, ensure regulatory integrity, and bring high-quality healthcare solutions to market more efficiently and ethically, while adhering to the highest compliance standards.

"This combination builds on our commitment to delivering innovative software, services, and support to life sciences companies across the globe," said Michael Allelunas, CEO of the new company. "Together, we combine our purpose-built platform of solutions to streamline global compliance, drive operational efficiency, and unlock new opportunities for our customers."

Leigh Powell, Chairman of the new company, added: "This merger represents a powerful alignment of mission and capability. We are excited to bring together our technologies, teams, and customers to provide the go-forward partner of choice for the life sciences industry. Our shared focus on innovation and client success will continue to guide us."

Clients and partners can expect uninterrupted service, increased investment in product development, and a clear commitment to a seamless integration experience. The company will continue to operate under both brand names in the near term, with a long-term vision to unify under a new common name which will be announced in the coming months.